360 related articles for article (PubMed ID: 27990776)
21. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
[TBL] [Abstract][Full Text] [Related]
23. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.
Nishimura R; Osonoi T; Kanada S; Jinnouchi H; Sugio K; Omiya H; Ubukata M; Sakai S; Samukawa Y
Diabetes Obes Metab; 2015 Aug; 17(8):800-4. PubMed ID: 25930989
[TBL] [Abstract][Full Text] [Related]
24. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Seino Y; Kaku K; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Endocr J; 2015; 62(7):593-603. PubMed ID: 25971406
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sasaki T; Sugawara M; Fukuda M
J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
[TBL] [Abstract][Full Text] [Related]
26. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
27. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
[TBL] [Abstract][Full Text] [Related]
28. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
29. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
[TBL] [Abstract][Full Text] [Related]
30. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
31. Effects of basic carbohydrate counting versus standard outpatient nutritional education (The BCC Study): study protocol for a randomised, parallel open-label, intervention study focusing on HbA1c and glucose variability in patients with type 2 diabetes.
Ewers B; Bruun JM; Vilsbøll T
BMJ Open; 2019 Nov; 9(11):e032893. PubMed ID: 31753900
[TBL] [Abstract][Full Text] [Related]
32. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
33. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes.
Brazeau AS; Mircescu H; Desjardins K; Leroux C; Strychar I; Ekoé JM; Rabasa-Lhoret R
Diabetes Res Clin Pract; 2013 Jan; 99(1):19-23. PubMed ID: 23146371
[TBL] [Abstract][Full Text] [Related]
34. Continuous glucose monitoring reveals different glycemic responses of moderate- vs high-carbohydrate lunch meals in people with type 2 diabetes.
Powers MA; Cuddihy RM; Wesley D; Morgan B
J Am Diet Assoc; 2010 Dec; 110(12):1912-5. PubMed ID: 21111100
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
36. Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
Kusunoki M; Natsume Y; Sato D; Tsutsui H; Miyata T; Tsutsumi K; Suga T; Oshida Y
Drug Res (Stuttg); 2016 Nov; 66(11):603-606. PubMed ID: 27626603
[TBL] [Abstract][Full Text] [Related]
37. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
38. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Chino Y; Kuwabara M; Hisatome I
J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
[TBL] [Abstract][Full Text] [Related]
39. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial.
Rizkalla SW; Taghrid L; Laromiguiere M; Huet D; Boillot J; Rigoir A; Elgrably F; Slama G
Diabetes Care; 2004 Aug; 27(8):1866-72. PubMed ID: 15277409
[TBL] [Abstract][Full Text] [Related]
40. Development of a New Tool to Assess Bolus Calculation and Carbohydrate Estimation.
Ehrmann D; Hermanns N; Reimer A; Weißmann J; Haak T; Kulzer B
Diabetes Technol Ther; 2016 Mar; 18(3):194-9. PubMed ID: 26907638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
